Login to Your Account



Filing Expected In First Half Of 2008

Theravance's Telavancin Meets Endpoint In Phase III HAP Trial

By Jennifer Boggs


Friday, December 7, 2007
Theravance Inc.'s antibiotic telavancin, deemed approvable earlier this year in complicated skin and skin structure infections caused by Gram-positive bacteria, achieved its endpoint in a second pivotal program in hospital-acquired pneumonia (HAP) patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription